New drug combo shows promise for Tough-to-Treat lymphomas
NCT ID NCT03259503
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 1 trial tested the safety and best dose of olaparib when added to high-dose chemotherapy for 50 patients with lymphomas that returned or didn't respond to treatment. All patients were scheduled for a stem cell transplant. The goal was to see if the combination could work better than chemotherapy alone, but the main focus was on side effects and dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (a PARP inhibitor) combined with high-dose chemotherapy (busulfan, gemcitabine, melphalan) and sometimes rituximab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat lymphomas who are undergoing a stem cell transplant.
- What could go wrong
- This is an early phase 1 trial with only 50 participants, so the main goal was safety and dosing, not effectiveness. The added drugs may increase side effects, and it's unclear if the combination works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- New combo approach aims to boost CAR-T success in tough lymphoma
- Can a weekly drug combo outsmart resistant lymphoma?